Children's Cancer Institute Australia
Total Page:16
File Type:pdf, Size:1020Kb
CHILDREN’S CANCER INSTITUTE AUSTRALIA (a company limited by guarantee) A.B.N. 41 072 279 559 Financial Report For the Year Ended 31 December 2020 Children’s Cancer Institute Australia Contents Directors’ Report 1 Responsible Entities’ Declaration 10 Auditor’s Independence Declaration 12 Independent Audit Report 13 Statement of Profit or Loss and Other Comprehensive Income 16 Statement of Financial Position 17 Statement of Cash Flows 18 Statement of Changes in Equity 19 Notes to the Financial Report 20 Children’s Cancer Institute Australia DIRECTORS’ REPORT The Directors present their report together with the financial report of Children’s Cancer Institute Australia (the “Institute”) for the year ended 31 December 2020 and the independent auditor’s report thereon. Directors The names of Directors in office during the financial year and at the date of this report and meetings attended during the year are as follows: Audit & Risk Date Date of Board Meetings Management Director appointed cessation Meetings No. of No. of No. of No. of meetings meetings meetings meetings held attended held attended Mr Simon Truskett 27-Mar-06 4 4 - - Professor Michelle Haber AM 01-Jun-00 4 4 4 4 Mrs Deborah Coakley 18-Jun-18 4 4 4 4 Emeritus Professor Richard Henry AM 12-Jan-99 4 4 2 2 Mrs Edwina Jones 15-Jun-10 4 4 - - Mr Mark Lazberger 19-Oct-20 2 2 - - ProfĞƐƐŽƌWilliam Ledger 19-Jun-17 16-Mar-20 1 1 - - Mr Simon Lewis 02-Sep-19 4 4 4 4 Professor Tracey O’Brien 16-Aug-19 4 3 - - Professor Vlado Perkovic 16-Mar-20 4 4 - - Mrs Jillian Skinner 16-Oct-17 4 4 - - Mr Bart Vogel 30-Jul-07 4 4 4 4 Emeritus Professor Leslie White AM 18-Nov-96 4 4 - - Directors were in office for the entire year unless otherwise stated. Qualifications, Experience and Special Responsibilities of Directors Simon Truskett BCom, LLB; GAICD Chairman Simon Truskett has more than 30 years' board level experience, including both advising boards and as a non-executive director. His executive career, before he retired as a partner of leading Australian law firm Clayton Utz, encompassed corporate governance, mergers and acquisitions, and a range of corporate and securities law issues in medical, health and other industries. He was the founding partner responsible for community involvement at Clayton Utz (called Community Connect) and was a director of the Clayton Utz Foundation. He is a former director and Chair of Lex Mundi Limited, the world's leading association of independent law firms. He is currently a non-executive director of Horizon Defence Systems and of Insitec MIS Systems. Simon has served on the Institute’s Board since 2006 and was appointed Chairman in December 2018. He is a member of the Remuneration Subcommittee and Chair of the Nominations Subcommittee. Page 1 Children’s Cancer Institute Australia DIRECTORS’ REPORT (continued) Qualifications, Experience and Special Responsibilities of Directors (continued) Michelle Haber AM, BSc (Psych) (Hons), PhD, Hon DSc (UNSW), FAHMS Executive Director Professor Michelle Haber AM was appointed the inaugural post-doctoral scientist at Children’s Cancer Institute in 1984. She became Director of the Institute in 2000 and has been Executive Director since 2003. She holds a conjoint appointment as Professor in the Faculty of Medicine at UNSW Australia. As Co-Head of the Molecular Targets and Cancer Therapeutics Theme and Head of the Experimental Therapeutics Group, Michelle’s current research focuses on developing effective treatments for children with neuroblastoma, and extending these treatments to other childhood malignancies, including brain tumours, leukaemia’s and sarcomas. She is also actively involved in developing a number of new research areas arising from the world leading Zero Childhood Cancer (ZERO) program. In 2007, Michelle was appointed a Member of the Order of Australia for her services to science in the field of research into childhood cancer, to scientific education and to the community. The following year, she was awarded an Honorary Doctorate from UNSW for her eminent service to the cancer research community. In 2014, she received the Cancer Institute NSW’s Premier’s Award for Outstanding Cancer Researcher of the Year, and in 2015 was appointed an inaugural Fellow of the Australian Academy of Health and Medical Sciences. Deborah Coakley Deborah Coakley was appointed a Board Director in 2018. She is the Executive General Manager of Funds Management at Dexus, one of Australia’s leading real estate groups. She has responsibility for managing its $15.5 billion funds management business which includes the Healthcare Wholesale Property Fund. Deborah has more than 25 years’ experience in management roles in consulting, human resources, and outsourcing, gained in organisations such as Deloitte, Qantas and Alexander Mann Solutions. She is an Ambassador for the Sydney Children’s Hospital Foundation, a Director of the Property Council of Australia and President of their Capital Markets Division, and a Committee Member for the Chief Executive Women Associations. She holds a Bachelor of Business degree from University of Technology Sydney and is a graduate of the Australian Institute of Company Directors. Deborah is Chair of the Remuneration Subcommittee and a member of the Nominations Subcommittee and the Audit and Risk Management Subcommittee. Richard Henry AM, MB BS, MD, Dip Clin Epi, FRACP, FRSN Emeritus Professor Richard Henry AM is a consultant in Health and Higher Education. He had a long career in academic medicine and hospital paediatrics before his appointment as Vice-President and Deputy Vice-Chancellor (Academic) of the University of NSW from 2006-2012. He is a Director of both Legal Aid NSW and Luminesce Alliance. Richard has been a Trustee at Sydney Grammar School since 2010 and was elected Chairman of Trustees in 2019. He was Pro-Chancellor of UNSW from 2014 to 2020 and Chair of the Centre for Social Impact from 2013 to 2018. In 2007, he was appointed a Member of the Order of Australia for service to paediatric respiratory medicine as a clinician, researcher, educator and mentor, and serving in a range of roles with professional medical organisations. Richard is a member of the Scientific Advisory Committee and Chair of the Comprehensive Children’s Cancer Centre Subcommittee. Page 2 Children’s Cancer Institute Australia DIRECTORS’ REPORT (continued) Qualifications, Experience and Special Responsibilities of Directors (continued) Edwina Jones BPharm Edwina Jones joined the Board in 2010. Prior to her retirement, she was a pharmacist, working in retail pharmacy and later as a consultant pharmacist. Edwina and her late husband, Spike – who was a Board member from 1993 to 1998 – have been long-time supporters of the Institute. Their daughter, Emma, is a childhood cancer survivor, having been diagnosed in 1991 with osteogenic sarcoma. Edwina sits on the Board of the Zero Childhood Cancer Capacity Campaign and is a member of the Remuneration and Nominations Subcommittee, and the Marketing & Fundraising Subcommittee. Mark Lazberger (Appointed to Board 19 October 2020) Mark is an accomplished investment management executive with more than 35 years’ experience working with large and successful organisations across Australia, Europe and Asia. He was most recently global CEO of Colonial First State Global Asset Management (now First Sentier Investors), a Sydney-based role he held from 2008-2018. His prior experience includes 17 years with State Street in a range of senior positions in Australia, Japan, and the UK. Mark currently serves on the boards of Yarra Capital Management and Fisher Funds Management (NZ), and is Co-Chair of the Zero Childhood Cancer Campaign Capacity Board. William Ledger MA, DPhil (Oxon), MB, ChB, FRCOG, FRANZCOG, CREI (Resigned from Board 16 March 2020) Professor William Ledger is Head of Obstetrics & Gynaecology at the University of New South Wales, Head of Reproductive Medicine at the Royal Hospital for Women, and Chair of the Research and Development Committee and a fertility specialist at IVF-Australia. Before moving to Sydney in 2011 he was Professor of Obstetrics and Gynaecology at the University of Sheffield from 1999, before which he was Reader in Obstetrics and Gynaecology at the University of Oxford. He was a Member of the UK Human Fertilisation and Embryology Authority for five years before his move to Australia and was Chair of the Royal College of Obstetricians and Gynaecologists Examinations and Assessment Committee for five years to 2010, and a Member of Council and Vice President of the RCOG. His research interests focus on in vitro fertilisation and assisted reproduction, impacts of reproductive ageing and disorders such as endometriosis, premature ovarian failure and polycystic ovary syndrome on fertility and quality of life, reproductive effects of cancer treatment and health economic and demographic aspects of infertility. He has published over 250 research papers and edited 11 books on aspects of reproductive medicine. Simon Lewis Simon was appointed to the Board in 2019. He is a Partner at ITNewcom, a wholly owned company of the national law firm MinterEllison. Simon has more than 25 years’ experience in managing and advising organisations in their effective use of Information Technology (IT). As a leader and practitioner in the development, implementation and delivery of IT transformations and improvements, he has advised and worked with many leading organisations and government entities in Australia and New Zealand, including Telstra, Macquarie Group, CBA, NSW Government, NSW iCare and AT Kearney Management Consultants. Simon is Chair of the Institute’s IT and Data Subcommittee and a member of the Audit & Risk Management Subcommittee. Page 3 Children’s Cancer Institute Australia DIRECTORS’ REPORT (continued) Qualifications, Experience and Special Responsibilities of Directors (continued) Tracey O’Brien FRACP, MBA, LLM (Health), MBBS, BSc Professor Tracey O’Brien is Director of the Kids Cancer Centre and Head of the Transplant and Cellular Therapies Program at Sydney Children's Hospital, Randwick.